Regenxbio Faces Class Action Over Alleged Misrepresentation of RGX-111 Safety and Efficacy

Regenxbio Faces Class Action Lawsuit Over RGX-111 Safety Concerns

Regenxbio is currently facing legal challenges as Robbins LLP files a class action lawsuit on behalf of investors who acquired shares of the biotechnology company between February 9, 2022, and January 27, 2026. The lawsuit centers around claims that Regenxbio misled investors about its leading gene therapy candidate, RGX-111, which is being developed to treat Mucopolysaccharidosis type I (MPS I). The complaint asserts that the company overstated the drug’s safety and efficacy, even as it faced serious safety concerns that were not disclosed to investors.

The timeline of RGX-111 has been marked by significant events, including the receipt of Fast Track designation from the FDA in 2018 and reports of positive outcomes from ongoing Phase I/II studies. However, as the lawsuit points out, internal knowledge of potential risks, specifically the possibility of central nervous system neoplasms, was allegedly withheld from shareholders. The situation escalates as, in November 2023, Regenxbio publicly announces a downscaling of RGX-111’s development efforts, which raises red flags regarding the viability of the therapy and the company’s transparency.

The pivotal moment comes on January 28, 2026, when the FDA places a clinical hold on RGX-111 after a neoplasm is reported in a clinical trial participant. This regulatory action coincides with an additional hold on another candidate, RGX-121, further compounding concerns about Regenxbio's overall development strategy. Following this announcement, the company's stock experiences a sharp decline of 17.8%, falling from $13.41 to $11.01 in a single trading session. Investors who believe they were misled by these statements have until April 14, 2026, to submit their lead plaintiff applications for participation in the lawsuit, which is structured on a contingency fee basis, meaning no fees will be incurred unless resources are recovered.

In light of the recent developments, the legal proceedings underscore the ongoing scrutiny that biopharmaceutical companies face in ensuring transparency and safety in their communications with investors. As the industry continues to evolve rapidly, the lessons from Regenxbio's challenges could shape future regulatory practices and corporate governance standards within biotech firms. For any stakeholders seeking further guidance, attorney Aaron Dumas, Jr., and Robbins LLP are available for inquiries related to the lawsuit.